All Stories

  1. Circadian astrocyte mitochondrial humanin regulates microglia and neuronal mitochondrial melatonergic pathway, with implications for aging and neurodegenerative conditions
  2. Glioblastoma pathophysiology: roles of aging driven changes in STAT3 interactions with NF-κB dimer components in the modulation of the mitochondrial melatonergic pathway and night-time inflammation resolution
  3. Enteric glial cell and astrocyte melatonin regulation in Parkinson disease pathogenesis and pathophysiology
  4. Autism Pathoetiology and Pathophysiology: Roles of STAT3 and NF-κB Dimer Interactions in Regulating the Mitochondrial Melatonergic Pathway in Placental, CNS, and Systemic Cells
  5. Natural Killer Cell Cytotoxicity: STAT3 Interactions with NF-<b>κ</b>B Dimer Composition Modulate Mitochondrial Melatonergic Pathway: Tumor, and Viral Infection Treatment Implications<sup>#</sup>
  6. Cannabinol Interactions With the Melatonergic Pathway
  7. Cannabinol interactions with the melatonergic pathway
  8. Diabetic cardiomyopathy: Role of the cardiac mitochondrial melatonergic pathway
  9. Physiological processes underpinning the ubiquitous benefits and interactions of melatonin, butyrate and green tea in neurodegenerative conditions
  10. Polycystic Ovary Syndrome Pathophysiology: Integrating Systemic, CNS and Circadian Processes
  11. A More Holistic Perspective of Alzheimer's Disease: Roles of Gut Microbiome, Adipocytes, HPA Axis, Melatonergic Pathway and Astrocyte Mitochondria in the Emergence of Autoimmunity
  12. Role of the Night-Time Systemic Processes and the Astrocyte Tryptophan-Melatonin Pathway in the Regulation of α-Synuclein and Wider Parkinson’s Disease Pathophysiology
  13. Gut Microbiome and Circadian Interactions with Platelets Across Human Diseases, including Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Cancer
  14. Melatonin, BAG-1 and cortisol circadian interactions in tumor pathogenesis and patterned immune responses
  15. Melatonin modulates tumor metabolism and mitigates metastasis
  16. Redefining Autoimmune Disorders’ Pathoetiology: Implications for Mood and Psychotic Disorders’ Association with Neurodegenerative and Classical Autoimmune Disorders
  17. Type I Diabetes Pathoetiology and Pathophysiology: Roles of the Gut Microbiome, Pancreatic Cellular Interactions, and the ‘Bystander’ Activation of Memory CD8+ T Cells
  18. Why do anti-amyloid beta antibodies not work? Time to reconceptualize dementia pathophysiology by incorporating astrocyte melatonergic pathway desynchronization from amyloid-beta production
  19. Amyotrophic Lateral Sclerosis Pathoetiology and Pathophysiology: Roles of Astrocytes, Gut Microbiome, and Muscle Interactions via the Mitochondrial Melatonergic Pathway, with Disruption by Glyphosate-Based Herbicides
  20. Depression Pathophysiology: Astrocyte Mitochondrial Melatonergic Pathway as Crucial Hub
  21. Tumor Microenvironment and Metabolism: Role of the Mitochondrial Melatonergic Pathway in Determining Intercellular Interactions in a New Dynamic Homeostasis
  22. Clozapine and the aryl hydrocarbon receptor
  23. Mitochondrial N-methyl-d-aspartate receptor activation enhances bioenergetics by calcium-dependent and –Independent mechanisms
  24. False Dogmas in Schizophrenia Research: Toward the Reification of Pathway Phenotypes and Pathway Classes
  25. Melatonin, Its Beneficial Effects on Embryogenesis from Mitigating Oxidative Stress to Regulating Gene Expression
  26. The melatonergic pathway and its interactions in modulating respiratory system disorders
  27. Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute Respiratory Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology
  28. Disrupted nocturnal melatonin in autism: Association with tumor necrosis factor and sleep disturbances
  29. Sirtuins, mitochondria, and the melatonergic pathway in Alzheimer’s disease
  30. Tumour Microenvironment: Roles of the Aryl Hydrocarbon Receptor, O-GlcNAcylation, Acetyl-CoA and Melatonergic Pathway in Regulating Dynamic Metabolic Interactions across Cell Types—Tumour Microenvironment and Metabolism
  31. Role of Opioidergic System in Regulating Depression Pathophysiology
  32. Mitochondria and immunity in chronic fatigue syndrome
  33. Inflammation and Mitochondrial Dysfunction in Autism Spectrum Disorder
  34. Chronic fatigue and depression due to multiple sclerosis: Immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways
  35. Preventive treatments to slow substantia nigra damage and Parkinson’s disease progression: A critical perspective review
  36. Aryl Hydrocarbon Receptor Role in Co-Ordinating SARS-CoV-2 Entry and Symptomatology: Linking Cytotoxicity Changes in COVID-19 and Cancers; Modulation by Racial Discrimination Stress
  37. Melatonin and cocaine: role of mitochondria, immunity, and gut microbiome
  38. COVID-19 pathophysiology: interactions of gut microbiome, melatonin, vitamin D, stress, kynurenine and the alpha 7 nicotinic receptor: Treatment implications
  39. Gut Dysbiosis Dysregulates Central and Systemic Homeostasis via Suboptimal Mitochondrial Function: Assessment, Treatment and Classification Implications
  40. Melatonin: Roles in influenza, Covid‐19, and other viral infections
  41. The Role of Prenatal Melatonin in the Regulation of Childhood Obesity
  42. Pathoetiology and pathophysiology of borderline personality: Role of prenatal factors, gut microbiome, mu- and kappa-opioid receptors in amygdala-PFC interactions
  43. The effects of melatonin on signaling pathways and molecules involved in glioma
  44. Integrating Autism Spectrum Disorder Pathophysiology: Mitochondria, Vitamin A, CD38, Oxytocin, Serotonin and Melatonergic Alterations in the Placenta and Gut
  45. Autism Spectrum Disorders: Role of Pre- and Post-Natal GammaDelta (γδ) T Cells and Immune Regulation
  46. Gut-Amygdala Interactions in Autism Spectrum Disorders: Developmental Roles via regulating Mitochondria, Exosomes, Immunity and microRNAs
  47. Autism Spectrum Disorder: Pathophysiology and Treatment Implications
  48. Early and very early‐onset schizophrenia compared with adult‐onset schizophrenia: French FACE‐SZ database
  49. Glioblastoma chemoresistance: roles of the mitochondrial melatonergic pathway
  50. The gut microbiome integrates immune-inflammatory processes in depression
  51. Daytime orexin and night-time melatonin regulation of mitochondria melatonin: roles in circadian oscillations systemically and centrally in breast cancer symptomatology
  52. Integrating Pathophysiology in Migraine: Role of the Gut Microbiome and Melatonin
  53. Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells
  54. The regulation of melatonin production within mitochondria reframes the nature of breast cancers
  55. The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia
  56. Left Ventricular Hypertrophy: Roles of Mitochondria CYP1B1 and Melatonergic Pathways in Co-Ordinating Wider Pathophysiology
  57. Endometriosis Pathoetiology and Pathophysiology: Roles of Vitamin A, Estrogen, Immunity, Adipocytes, Gut Microbiome and Melatonergic Pathway on Mitochondria Regulation
  58. Mitochondria and the Gut as crucial hubs for the interactions of melatonin with sirtuins, inflammation, butyrate, tryptophan metabolites, and alpha 7 nicotinic receptor across a host of medical conditions.
  59. Mitochondria: the birth place, battle ground and the site of melatonin metabolism in cells
  60. Depression and neuroprogression: Sirtuins and mitochondria as crucial hubs
  61. Reframes nature of GBM and GSCs
  62. Common Environmental Factors May Underpin the Comorbidity Between Generalized Anxiety Disorder and Mood Disorders Via Activated Nitrooxidative Pathways
  63. The neurobiology of adaptation to seasons: Relevance and correlations in bipolar disorders
  64. Lowered quality of life in mood disorders is associated with increased neuro-oxidative stress and basal thyroid-stimulating hormone levels and use of anticonvulsant mood stabilizers
  65. In major affective disorders, early life trauma predict increased nitro-oxidative stress, lipid peroxidation and protein oxidation and recurrence of major affective disorders, suicidal behaviors and a lowered quality of life
  66. Reciprocal Interactions of Mitochondria and the Neuroimmunoendocrine System in Neurodegenerative Disorders: An Important Role for Melatonin Regulation
  67. Bright light and oxygen therapies decrease delirium risk in critically ill surgical patients by targeting sleep and acid-base disturbances
  68. A neuro-immune, neuro-oxidative and neuro-nitrosative model of prenatal and postpartum depression
  69. Associations between severity of anxiety and clinical and biological features of major affective disorders
  70. Linking the biological underpinnings of depression: Role of mitochondria interactions with melatonin, inflammation, sirtuins, tryptophan catabolites, DNA repair and oxidative and nitrosative stress, with consequences for classification and cognition
  71. Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs
  72. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition
  73. The Biological Underpinnings of Mood Disorders Interact With Early Trauma, Sexual Abuse and Neuroticism: Implications for Psychiatric Classification and Treatment
  74. Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia
  75. Psychosis: glia, immunity, and melatonin
  76. Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders
  77. Oxidative and Nitrosative Stress, Immune Inflammation and Trptophan Catabolites in Driving Melatonergic Pathway Alterations in Depression: Treatment Implications
  78. IgA/IgM Responses to Gram-Negative Bacteria are not Associated with Perinatal Depression, but with Physio-somatic Symptoms and Activation of the Tryptophan Catabolite Pathway at the End of Term and Postnatal Anxiety
  79. IgM-mediated autoimmune responses to oxidative specific epitopes, but not nitrosylated adducts, are significantly decreased in pregnancy: association with bacterial translocation, perinatal and lifetime major depression and the tryptophan catabolite (T...
  80. Increased Root Canal Endotoxin Levels are Associated with Chronic Apical Periodontitis, Increased Oxidative and Nitrosative Stress, Major Depression, Severity of Depression, and a Lowered Quality of Life
  81. How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
  82. Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation
  83. Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway
  84. Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid
  85. Breastfeeding and the gut-brain axis: is there a role for melatonin?
  86. Interactions of Tryptophan and Its Catabolites With Melatonin and the Alpha 7 Nicotinic Receptor in Central Nervous System and Psychiatric Disorders: Role of the Aryl Hydrocarbon Receptor and Direct Mitochondria Regulation
  87. Alpha 7 Nicotinic Receptor Agonist Modulatory Interactions with Melatonin: Relevance not only to Cognition, but to Wider Neuropsychiatric and Immune Inflammatory Disorders
  88. Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
  89. Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
  90. Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes
  91. A Role for the Regulation of the Melatonergic Pathways in Alzheimer’s Disease and Other Neurodegenerative and Psychiatric Conditions
  92. Single-Nucleotide Polymorphisms of Genes Involved in Repair of Oxidative DNA Damage and the Risk of Recurrent Depressive Disorder
  93. Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways
  94. Breast Feeding and Melatonin: Implications for Improving Perinatal Health
  95. Direct exposure to N-methyl-d-aspartate alters mitochondrial function
  96. T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model
  97. IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome
  98. Morphofunctional and signaling molecules overlap of the pineal gland and thymus: role and significance in aging
  99. Bipolar Disorder: The Role of the Kynurenine and Melatonergic Pathways
  100. Editorial (Thematic Issue: The Kynurenine and Melatonergic Pathways in Psychiatric and CNS Disorders)
  101. Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
  102. Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer';s Disease
  103. The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders
  104. Incidence of Diabetes in Colorectal Cancer Survivors
  105. Melatoninergic Pathways in Alzheimer's Disease
  106. Pharmaceutical and Nutritional Benefits in Alzheimer's Disease via Convergence on the Melatoninergic Pathways
  107. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut–brain pathways
  108. The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
  109. The gut–brain axis: The role of melatonin in linking psychiatric, inflammatory and neurodegenerative conditions
  110. Multiple sclerosis: The role of melatonin and N-acetylserotonin
  111. Bipolar Disorder: Role of Immune-Inflammatory Cytokines, Oxidative and Nitrosative Stress and Tryptophan Catabolites
  112. Melatonin (High Dose): A neglected aspect of managing the Ebola virus
  113. Mechanisms Underlying Neurocognitive Dysfunctions in Recurrent Major Depression
  114. Oxidative & nitrosative stress in depression: Why so much stress?
  115. Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders
  116. Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
  117. The Glutathione System: A New Drug Target in Neuroimmune Disorders
  118. Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala
  119. Targeting classical IL-6 signalling or IL-6trans-signalling in depression?
  120. TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
  121. Reconceptualizing Adult Neurogenesis: Role for Sphingosine-1-Phosphate and Fibroblast Growth Factor-1 in Co-Ordinating Astrocyte-Neuronal Precursor Interactions
  122. Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression
  123. Immunolocalization of substance P and NK-1 receptor in hofbauer cells in human normal placenta
  124. Role of Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways in the Etiology of Depression: Therapeutic Implications
  125. Melatonin in the Etiology, Pathophysiology, and Management of Schizophrenia
  126. Metabolic Syndrome, Alzheimer Disease, Schizophrenia, and Depression: Role for Leptin, Melatonin, Kynurenine Pathways, and Neuropeptides
  127. Neurodegeneration in Parkinson's Disease: Interactions of Oxidative Stress, Tryptophan Catabolites and Depression with Mitochondria and Sirtuins
  128. In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation
  129. Biological phenotypes: somatization, depression, and chronic fatigue syndrome.
  130. Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: Implications for the pathways to chronic depression and neuroprogression
  131. Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications
  132. Comment and reply on: ME is a distinct diagnostic entity, not part of a chronic fatigue spectrum
  133. The circadian clock circuitry and the AHR signaling pathway in physiology and pathology
  134. Prenatal infection important to etiology of schizophrenia
  135. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways
  136. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia
  137. Putative neuroprotective agents in neuropsychiatric disorders
  138. A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior
  139. Diagnosis of myalgic encephalomyelitis: where are we now?
  140. Postpartum depression: psychoneuroimmunological underpinnings and treatment
  141. Identification of an N-Methyl-d-aspartate Receptor in Isolated Nervous System Mitochondria
  142. Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells
  143. Hemochromatosis and bipolar disorder
  144. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways
  145. Biological underpinnings of the commonalities in depression, somatization & Chronic Fatigue Syndrome
  146. Melatonin prevents the metabolic dysregulation by anti-psychotics
  147. The Role of Indoleamine 2,3-Dioxygenase in a Mouse Model of Neuroinflammation-Induced Depression
  148. Inflammation-Related Disorders in the Tryptophan Catabolite Pathway in Depression and Somatization
  149. Melatonin and Cognitive Deficits in Bipolar Disorder and Mild Cognitive Impairment
  150. Multiple sclerosis and seizures: possible role forHelicobacter pylori
  151. Melatonin, Agomelatine, and Alcoholism
  152. Primary role of mitochondrial Rieske iron–sulfur protein in hypoxic ROS production in pulmonary artery myocytes
  153. Amygdala has early postnatal role in regulation of cortex development
  154. Hypoxia Induces Intracellular Ca 2+ Release by Causing Reactive Oxygen Species-Mediated Dissociation of FK506-Binding Protein 12.6 from Ryanodine Receptor 2 in Pulmonary Artery Myocytes
  155. Role of IL-18, IDO and melatonin in emergent seizures in MS patients
  156. Impact of prenatal corticosteroids and modulation by melatonin and vitamin D
  157. IL-18, IDO and quinolinic acid drive emergent seizures in Alzheimer's disease
  158. The role of melatonin in post-partum psychosis and depression associated with bipolar disorder
  159. Membrane depolarization causes a direct activation of G protein-coupled receptors leading to local Ca 2+ release in smooth muscle
  160. Protein Kinase C-ε Regulates Local Calcium Signaling in Airway Smooth Muscle Cells
  161. Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca2+]i through the mitochondrial ROS-PKCɛ signaling axis in pulmonary artery smooth muscle cells
  162. Post-Injury Administration of Mitochondrial Uncouplers Increases Tissue Sparing and Improves Behavioral Outcome following Traumatic Brain Injury in Rodents
  163. Protective Effects of NIM811 in Transient Focal Cerebral Ischemia Suggest Involvement of the Mitochondrial Permeability Transition
  164. The Uncoupling Agent 2,4-Dinitrophenol Improves Mitochondrial Homeostasis following Striatal Quinolinic Acid Injections
  165. The mitochondrial uncoupler 2,4‐dinitrophenol attenuates tissue damage and improves mitochondrial homeostasis following transient focal cerebral ischemia
  166. Mitochondrial uncoupling as a potential therapeutic target in acute central nervous system injury
  167. Some applications of reversal theory to the explanation of gambling and gambling addictions
  168. First study to show heart rate increase in gamblers and correlated with personality
  169. Alcohol cues condition changes in arousal